Results 231 to 240 of about 89,687 (340)

Cannabinoids and Adverse Convulsive Effects: A Pharmacovigilance and Addictovigilance Analysis of Cases Reported in France

open access: yesFundamental &Clinical Pharmacology, Volume 39, Issue 4, August 2025.
ABSTRACT Background Seizures after the use of cannabinoids are reported, but no precise descriptions of the characteristics of subjects and factors that may trigger seizures are available. Objectives To study the characteristics and circumstances associated with the occurrence of seizures in individuals using cannabinoids for medical or recreational ...
Marie‐Laure Laroche   +4 more
wiley   +1 more source

Induction of CYP1A2 activity by carbamazepine in children using the caffeine breath test [PDF]

open access: green, 1998
A.C. Parker   +3 more
openalex   +1 more source

Fluoxetine Treatment in Epilepsy of Infancy with Migrating Focal Seizures Due to KCNT1 Variants: An Open Label Study

open access: yesAnnals of Neurology, Volume 98, Issue 1, Page 48-61, July 2025.
Objective Gain‐of‐function (GoF) variants in KCNT1 encoding for potassium channels are associated with different epilepsy phenotypes, including epilepsy of infancy with migrating focal seizures (EIMFS), other early infantile developmental and epileptic encephalopathies, and focal epilepsy.
Marina Trivisano   +13 more
wiley   +1 more source

Rocuronium-induced Neuromuscular Block Is Affected by Chronic Carbamazepine Therapy [PDF]

open access: bronze, 1999
Anna Spacek   +4 more
openalex   +1 more source

Pharmacology and relevant drug interactions of metamizole

open access: yesBritish Journal of Clinical Pharmacology, Volume 91, Issue 7, Page 2095-2102, July 2025.
Metamizole is a frequently prescribed analgesic because of its favourable benefit/risk ratio compared with classic NSAIDs. However, increasing research shows that metamizole displays several drug interactions that are relevant to clinical practice. We reviewed the literature to summarize the pharmacology and most clinically relevant drug interactions ...
David J. Brinkman   +3 more
wiley   +1 more source

Use of Real‐World Claims Data to Assess the Prevalence of Concomitant Medications to Inform Drug–Drug Interaction Risk in Target Patient Populations

open access: yesClinical Pharmacology &Therapeutics, Volume 118, Issue 1, Page 146-155, July 2025.
A common issue in clinical drug development involves drug–drug interactions (DDI) that may lead to altered drug exposure and subsequent altered safety and efficacy of an investigational drug or concomitant medications (conmeds) in the target patient population.
Alice S. Tang   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy